--- title: "Board Member At AtriCure Exercises Options Worth $491K" type: "News" locale: "en" url: "https://longbridge.com/en/news/294530665.md" description: "Sven Wehrwein, a board member at AtriCure (NASDAQ:ATRC), exercised stock options for 25,000 shares on July 30, as reported in an SEC Form 4 filing. The exercise price was $19.95 per share, making the transaction worth approximately $491,500. This insider activity coincides with AtriCure's stock trading down by 6.06% to $39.61." datetime: "2026-07-31T15:01:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294530665.md) - [en](https://longbridge.com/en/news/294530665.md) - [zh-HK](https://longbridge.com/zh-HK/news/294530665.md) generator: "portal-rs" --- # Board Member At AtriCure Exercises Options Worth $491K A significant insider transaction involving the exercise of company stock options was reported on July 30, by **Sven Wehrwein**, Board Member at **AtriCure** (NASDAQ:ATRC), as per the latest SEC filing. **What Happened:** A Form 4 filing with the U.S. Securities and Exchange Commission on Thursday revealed that Wehrwein, Board Member at AtriCure in the Health Care sector, exercised stock options for 25,000 shares of ATRC stock. The exercise price of the options was $19.95 per share. The latest update on Friday morning shows **AtriCure** shares down by 6.06%, trading at $39.61. At this price, Wehrwein's 25,000 shares are worth $491,500. ### Unveiling the Story Behind AtriCure AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. ### Financial Milestones: AtriCure's Journey **Revenue Growth:** AtriCure's remarkable performance in 3 months is evident. As of 30 June, 2026, the company achieved an impressive revenue growth rate of **12.83%**. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector. **Profitability Metrics:** - Gross Margin: The company excels with a remarkable gross margin of 77.23%, indicating superior cost efficiency and profitability compared to its industry peers. - Earnings per Share (EPS): With an EPS below industry norms, AtriCure exhibits below-average bottom-line performance with a current EPS of 0.18. **Debt Management:** AtriCure's debt-to-equity ratio is below the industry average at **0.14**, reflecting a lower dependency on debt financing and a more conservative financial approach. **Valuation Metrics:** - Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 191.29, the stock indicates an attractive valuation, potentially presenting a buying opportunity. - Price to Sales (P/S) Ratio: The current P/S ratio of 3.42 is above industry norms, reflecting an elevated valuation for AtriCure's stock and potential overvaluation based on sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Boasting an EV/EBITDA ratio of 50.46, AtriCure demonstrates a robust market valuation, outperforming industry benchmarks. **Market Capitalization:** Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges. ### Illuminating the Importance of Insider Transactions While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process. From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction. A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock. While insider sells may not necessarily reflect a bearish view and can be motivated by various factors. ### Unlocking the Meaning of Transaction Codes When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase,while **S** signifies a sale. Transaction code **C** signals the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of AtriCure's Insider Trades. *This article was generated by Benzinga's automated content engine and reviewed by an editor.* ### Related Stocks - [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md) ## Related News & Research - [Director At AtriCure Sells $134K Of Stock](https://longbridge.com/en/news/295252263.md) - [AtriCure director Maggie Yuen sells 3,500 shares worth $134,470](https://longbridge.com/en/news/295241364.md) - [Truist Just Upped Its Price Target on Snowflake Stock. Here's Why.](https://longbridge.com/en/news/296634787.md) - [Congressman Shri Thanedar Disclosed a January Apple Stock Sale Worth up to $250,000 171 Days After the Legal Deadline](https://longbridge.com/en/news/296655935.md) - [AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares](https://longbridge.com/en/news/294417197.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**